한글목차

기침 과민 증후군 치료 시장 규모는 2025년 35억 6,000만 달러에서 2034년에는 72억 6,000만 달러에 이를 것으로 예측되며, 2026-2034년 CAGR 8.23%를 나타낼 전망입니다.

기침 과민 증후군 치료 시장은 이 질환에 대한 인식이 높아지고 효과적인 치료법에 대한 수요가 증가함에 따라 큰 폭의 성장이 예상됩니다. 기침 과민 증후군은 과도한 기침 반사가 특징이며 환자의 삶의 질에 심각한 영향을 미칠 수 있으며 천식, 만성폐쇄성폐질환(COPD), 후비루 등 기저질환과 관련이 있는 경우가 많습니다. 기침 과민증이 독립적인 임상 실체로 인식되면서 표적치료제 연구개발에 대한 투자가 촉진되어 시장이 더욱 확대되고 있습니다.

기술 발전은 기침 과민 증후군 치료 시장 전망상을 형성하는 데 중요한 역할을 하고 있습니다. 새로운 계열의 진해제와 항염증제를 포함한 약리학적 치료법의 혁신으로 이 증후군의 관리가 개선되고 있습니다. 또한, 기침 과민증의 여러 근본 원인을 다루는 병용 요법의 개발이 진행되고 있습니다. 제약회사들이 연구개발과 임상시험에 대한 투자를 지속하고 있는 가운데, 효과적인 치료법의 채택이 시장에서 증가할 것으로 예측됩니다.

또한, 환자 중심의 치료와 개인 맞춤형 의료에 대한 관심이 높아지는 것도 기침 과민성 증후군 치료 시장의 성장 궤도에 영향을 미치고 있습니다. 의료진이 환자 개개인의 필요에 맞는 치료법을 모색하는 가운데, 기침 과민증과 관련된 특정 유발 요인과 기저 질환을 고려한 치료법에 대한 수요가 증가하고 있습니다. 이러한 추세는 연구자, 임상의사, 제약사 간의 협력을 촉진하고 환자 치료 결과를 개선하는 통합 솔루션 개발을 촉진하고 있습니다. 시장이 계속 진화하는 가운데, 기술, 개인 맞춤형 의료, 환자 참여의 통합이 성공의 열쇠가 될 것입니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 기침 과민 증후군 치료 시장 : 치료 유형별

제5장 세계의 기침 과민 증후군 치료 시장 : 투여 경로별

제6장 세계의 기침 과민 증후군 치료 시장 : 최종사용자별

제7장 세계의 기침 과민 증후군 치료 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Cough Hypersensitivity Syndrome Treatment Market size is expected to reach USD 7.26 Billion in 2034 from USD 3.56 Billion (2025) growing at a CAGR of 8.23% during 2026-2034.

The Cough Hypersensitivity Syndrome Treatment Market is poised for significant growth as awareness of this condition increases and the demand for effective treatment options rises. Cough hypersensitivity syndrome, characterized by an exaggerated cough reflex, can significantly impact patients' quality of life and is often associated with underlying conditions such as asthma, chronic obstructive pulmonary disease (COPD), and postnasal drip. The growing recognition of cough hypersensitivity as a distinct clinical entity is driving investments in research and development of targeted therapies, further propelling market expansion.

Technological advancements are playing a crucial role in shaping the future of the cough hypersensitivity syndrome treatment market. Innovations in pharmacological treatments, including new classes of cough suppressants and anti-inflammatory medications, are enhancing the management of this condition. Additionally, the development of combination therapies that address multiple underlying causes of cough hypersensitivity is gaining traction. As pharmaceutical companies continue to invest in research and clinical trials, the market is likely to see increased adoption of effective treatment options.

Moreover, the growing emphasis on patient-centered care and personalized medicine is influencing the cough hypersensitivity syndrome treatment market's growth trajectory. As healthcare providers seek to tailor treatments to individual patient needs, there is a rising demand for therapies that consider the specific triggers and underlying conditions associated with cough hypersensitivity. This trend is driving collaboration between researchers, clinicians, and pharmaceutical companies to develop integrated solutions that enhance patient outcomes. As the market continues to evolve, the integration of technology, personalized care, and patient engagement will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Pharmacological Treatments
• Non-Pharmacological Treatments

By Route of Administration

• Oral
• Inhalation
• Others

By End-User

• Hospitals
• Specialty Clinics
• Homecare
• Others

COMPANIES PROFILED

• Johnson Johnson, Bayer AG, GlaxoSmithKline plc, Pfizer Inc, Novartis AG, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Merck Co Inc, Sanofi, Boehringer Ingelheim GmbH, BristolMyers Squibb Company, Takeda Pharmaceutical Company Limited

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Pharmacological Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Pharmacological Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Johnson & Johnson
  • 9.2.2 Bayer AG
  • 9.2.3 GlaxoSmithKline Plc
  • 9.2.4 Pfizer Inc
  • 9.2.5 Novartis AG
  • 9.2.6 AstraZeneca PLC
  • 9.2.7 Teva Pharmaceutical Industries Ltd
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 Sanofi
  • 9.2.10 Boehringer Ingelheim GmbH
  • 9.2.11 Bristol-Myers Squibb Company
  • 9.2.12 Takeda Pharmaceutical Company Limited